Syngene International — 360° view

Syngene International, a company in the Healthcare Research, Analytics & Technology industry, reported revenue of ₹833 crore and net profit of ₹32 crore for the September 2026 quarter.

Syngene International (NSE: SYNGENE) closed at ₹451.70 on 20 Nov 2026, down 28.8% over the past year. Its market capitalisation is ₹18,234 crore and it trades at 68.6 times earnings.

Share price
₹451.70 (20 Nov 2026)
Market cap
₹18,234 Cr (20 Nov 2026)
P/E
68.58 (20 Nov 2026)
Revenue
₹833 Cr (September 2026 quarter)
Net profit
₹32 Cr (September 2026 quarter)
ROCE
9.99% (FY26)
ROE
7.78% (FY26)
Book value
₹120 (FY26)
Dividend yield
0.28% (last 12 months to 20 Nov 2026)
52-week high / low
₹678.95 / ₹344.45 (20 Nov 2026)
1-year return
-28.8% (to 20 Nov 2026)
Sector
Healthcare
Industry
Healthcare Research, Analytics & Technology
Symbol
NSE: SYNGENE

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.